Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) FCF Margin (2022 - 2026)

Axsome Therapeutics' FCF Margin history spans 5 years, with the latest figure at 10.89% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 2510.0% to 10.89% in Q1 2026 year-over-year; TTM through Mar 2026 was 10.02%, a 2783.0% increase, with the full-year FY2025 number at 14.7%, up 1866.0% from a year prior.
  • FCF Margin hit 10.89% in Q1 2026 for Axsome Therapeutics, down from 9.55% in the prior quarter.
  • Over the last five years, FCF Margin for AXSM hit a ceiling of 0.58% in Q3 2025 and a floor of 5246.4% in Q4 2024.
  • Historically, FCF Margin has averaged 396.3% across 5 years, with a median of 39.22% in 2023.
  • Biggest five-year swings in FCF Margin: crashed -520394bps in 2024 and later soared 523685bps in 2025.
  • Tracing AXSM's FCF Margin over 5 years: stood at 113.84% in 2022, then soared by 63bps to 42.46% in 2023, then crashed by -12257bps to 5246.4% in 2024, then surged by 100bps to 9.55% in 2025, then fell by -14bps to 10.89% in 2026.
  • Business Quant data shows FCF Margin for AXSM at 10.89% in Q1 2026, 9.55% in Q4 2025, and 0.58% in Q3 2025.